Demonstrates less chromosomal damage with shorter radiotherapy schemes in breast cancer patients, suggesting better long-term safety.
Shorter RT scheme with higher dose per fraction may mitigate cytogenetic damage in circulating lymphocytes, offering potential advantages in long-term safety profiles. In vitro chromosomal radiosensitivity, as assessed by CBMN assay is not a hallmark for second primary BC risk.
No takes yet. Share an insight, caveat, or question.
Dayal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: